BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38436700)

  • 1. Image-defined risk factors associated with MYCN oncogene amplification in neuroblastoma and their association with overall survival.
    Wang H; Li T; Ni X; Chen X; He L; Cai J
    Abdom Radiol (NY); 2024 Mar; ():. PubMed ID: 38436700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma.
    Zhang AA; Pan C; Xu M; Wang XX; Ye QD; Gao YJ; Tang JY
    World J Pediatr; 2019 Dec; 15(6):572-579. PubMed ID: 31342464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association of Clinical Characteristics and Tumour Markers With Image-Defined Risk Factors in the Management of Neuroblastoma in South Africa.
    van Heerden J; Esterhuizen TM; Hendricks M; Poole J; Büchner A; Naidu G; du Plessis J; van Emmenes B; van Zyl A; Mathews E; Kruger M;
    Clin Oncol (R Coll Radiol); 2022 Apr; 34(4):e149-e159. PubMed ID: 34750056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of preoperative chemotherapy on neuroblastoma with
    Chui C
    World J Pediatr Surg; 2020; 3(2):e000129. PubMed ID: 36474920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.
    Temple WC; Vo KT; Matthay KK; Balliu B; Coleman C; Michlitsch J; Phelps A; Behr S; Zapala MA
    Cancer Med; 2021 Apr; 10(7):2232-2241. PubMed ID: 33314708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in image-defined risk factors with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma.
    Wang H; Chen X; Zhu J; Zhang K; Lu J; Zhang L; Ding H; He L
    Abdom Radiol (NY); 2022 Oct; 47(10):3520-3530. PubMed ID: 35790567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
    Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S
    Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between image-defined risk factors and neuroblastoma outcomes.
    Phelps HM; Ndolo JM; Van Arendonk KJ; Chen H; Dietrich HL; Watson KD; Hilmes MA; Chung DH; Lovvorn HN
    J Pediatr Surg; 2019 Jun; 54(6):1184-1191. PubMed ID: 30885556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma.
    Tan E; Merchant K; Kn BP; Cs A; Zhao JJ; Saffari SE; Tan PH; Tang PH
    Childs Nerv Syst; 2022 Aug; 38(8):1487-1495. PubMed ID: 35460355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography/computed tomography parameters for MYCN amplification in high-risk neuroblastoma.
    Li S; Liu J; Wang G; Feng L; Yang X; Kan Y; Wang W; Yang J
    Eur J Radiol; 2024 Jan; 170():111243. PubMed ID: 38043380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
    Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
    [No Abstract]   [Full Text] [Related]  

  • 20. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.